Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"3P Biopharmaceuticals","sponsor":"Toleranzia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"3P Bio and Toleranzia Enter Orphan Drug Partnership","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"3P Biopharmaceuticals","sponsor":"SpyBiotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"3 P Biopharmaceuticalsandd Spy Biotech Enter Into a Vaccine Contract Manufacturing Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Vaccine","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"3P Biopharmaceuticals","sponsor":"Buzzard Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"3P Biopharmaceuticals and Buzzard Pharmaceuticals Start a Collaboration to Develop a New Treatment to Combat Solid Tumours","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by 3P Biopharmaceuticals

    Menu

    3P Biopharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              3P Biopharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              3P Biopharmaceuticals and Buzzard Pharmaceuticals Start a Collaboration to Develop a New Treatment to Combat Solid Tumours

              Details:

              3P Biopharmaceuticals and Buzzard Pharmaceuticals have entered into a partnership agreement for manufacturing of the potent IL-1 inhibitor Isunakinra, a recombinant protein for cancer indications.

              Lead Product(s): Isunakinra

              Therapeutic Area: Oncology Product Name: EBI-005

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Buzzard Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 07, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              3P Biopharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              3 P Biopharmaceuticalsandd Spy Biotech Enter Into a Vaccine Contract Manufacturing Agreement

              Details:

              SpyBiotech selected 3P Biopharmaceuticals in June 2019 to manufacture a cGMP batch of their virus-like-particle carrier with the goal of completing production in 2021. This carrier will be used to display antigens from different pathogens.

              Lead Product(s): VLPs based vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: SpyBiotech

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 27, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              3P Biopharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              3P Bio and Toleranzia Enter Orphan Drug Partnership

              Details:

              Toleranzia’s innovative candidate (TOL2) is being developed for the treatment of the autoimmune neuromuscular disease Myasthenia Gravis (MG), an orphan disease, which has a major unmet medical need and a large market potential.

              Lead Product(s): TOL2

              Therapeutic Area: Immunology Product Name: TOL2

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Toleranzia

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership June 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY